Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease

Atherosclerosis

Volumn 197, Issue 1, 2008, Pages 154-158

  Hayashi, Toshiyuki ^a   Hirano, Tsutomu ^a   Taira, Takayasu ^b   Tokuno, Anna ^a   Mori, Yusaku ^a   Koba, Shinji ^a   Adachi, Mitsuru ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Yokohama Dai ichi Hospital   (Japan)

Author keywords

Apolipoprotein B48; Diabetic nephropathy; Dyslipidemia; End stage renal disease

Indexed keywords

APOLIPOPROTEIN B48; CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALBUMINURIA; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DYSLIPIDEMIA; FEMALE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ALBUMINURIA; APOLIPOPROTEIN B-48; CHYLOMICRONS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DYSLIPIDEMIAS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RISK FACTORS;

EID: 39449134285     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.03.015     Document Type: Article

References (32)

1. United States Renal Data System. USRDS 1998 annual data report, excerpts from V and VI. J Kidney Dis 1998;2(Suppl 1):S69-80, S81-8.
2. Hahn R., Oette K., Mondorf H., Finke K., and Sieberth H.G. Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias. Atherosclerosis 48 (1983) 279-288
3. Cheung A.K., Sarnak M.J., Yan G., et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58 (2000) 353-362
4. Valmadrid C.T., Klein R., Moss S.E., and Klein B.E. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 160 (2000) 1093-1100
5. Attman P.-O., Knight-Gibson C., Tavella M., Samuelsson O., and Alaupovic P. The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant 13 (1998) 2833-2841
6. Hirano T. Lipoprotein abnormalities in diabetic nephropathy. Kidney Int 71 (1999) S22-S24
7. Jensen T., Borch-Johnsen K., Kofoed-Enevoldsen A., and Deckert T. Coronary heart disease in young Type1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia 30 (1987) 144-148
8. De Cosmo S., Bacci S., Piras G.P., et al. High prevalence of risk factors for cardiovascular disease in parents of IDDM patients with albuminuria. Diabetologia 40 (1997) 1191-1196
9. Kashiwazaki K., Hirano T., Yoshino G., et al. Decreased release of lipoprotein lipase is associated with vascular endothelial damage in NIDDM patients with microalbuminuria. Diab Care 21 (1998) 2016-2020
10. Hirano T., Sakaue T., Misaki A., et al. Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII. Kidney Int 63 (2003) 2171-2177
11. Wilhelm M.G., and Cooper A.D. Induction of atherosclerosis by human chylomicron remnants: a hypothesis. J Atheroscler Thromb 10 (2003) 132-139
12. Proctor S.D., Vine D.F., and Mamo J.C. Arterial permeability and efflux of apolipoprotein B-containing lipoproteins assessed by in situ perfusion and three-dimensional quantitative confocal microscopy. Arterioscler Thromb Vasc Biol 24 (2004) 2162-2167
13. Proctor S.D., and Mamo J.C. Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol 23 (2003) 1595-1600
14. Pal S., Semorine K., Watts G.F., and Mamo J. Identification of lipoproteins of intestinal origin in human atherosclerotic plaque. Clin Chem Lab Med 41 (2003) 792-795
15. Redgrave T.G. Chylomicron metabolism. Biochem Soc Trans 32 (2004) 79-82
16. Brown M.L., Ramprasad M.P., Umeda P.K., et al. A macrophage receptor for apolipoprotein B48: cloning, expression and atherosclerosis. Proc Natl Acad Sci USA 97 (2000) 7488-7493
17. Flood C., Gustafsson M., Richardson P.E., et al. Identification of the proteoglycan binding site in apolipoprotein B48. J Biol Chem 277 (2002) 32228-32233
18. Sakai N., Uchida Y., Ohashi K., et al. Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA. J Lipid Res 44 (2003) 1256-1262
19. Sakai N., Sugimoto T., Tsujii K., et al. Fasting apolipoprotein B48 levels measured by a novel ELISA are a simple and useful marker for postprandial hyperlipidemia and predict coronary heart disease. Circulation 17 (2004) III-183 [abstract]
20. Hirano T., Oi K., Sakai S., Kashiwazaki K., Adachi M., and Yoshino G. High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage: a possible role of postprandial lipemia. Atherosclerosis 141 (1998) 77-85
21. Sakaue T., Hirano T., Yoshino G., et al. The influence of diabetic nephropathy on remnant lipoproteins. J Jpn Diab Soc 42 (1999) 439-446 [abstract in English]
22. Nakajima K., Saito T., Tamura A., et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 31 223 (1993) 53-71
23. Campos H., Khoo C., and Sacks F.M. 22. Diurnal and acute patterns of postprandial apolipoprotein B-48 in VLDL, IDL, and LDL from normolipidemic humans. Atherosclerosis 181 (2005) 345-351
24. Jackson K.G., and Williams C.M. Apolipoprotein B-48: comparison of fasting concentrations measured in normolipidaemic individuals using SDS-PAGE, immunoblotting and ELISA. Atherosclerosis 176 (2004) 207-217
25. Weintraub M., Burstein A., Rassin T., et al. Severe defect in clearing postprandial chylomicron remnants in dialysis patients. Kidney Int 42 (1992) 1247-1252
26. Kim C., and Vaziri N.D. Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int 67 (2005) 1028-1032
27. Vaziri N.D., and Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int 50 (1996) 1928-1935
28. Dichek H.L., Qian K., and Agrawal N. The bridging function of hepatic lipase clears plasma cholesterol in LDL receptor-deficient "apoB-48-only" and "apoB-100-only" mice. J Lipid Res 45 (2004) 551-560
29. Campos E., Kotite L., Blanche P., et al. Properties of triglyceride-rich and cholesterol-rich lipoproteins in the remnant-like particle fraction of human blood plasma. J Lipid Res 43 (2002) 365-374
30. Duez H., Lamarche B., Uffelman K.D., et al. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Atheroscler Thromb Vasc Biol 26 (2006) 1357-1363
31. Valero R., Lorec A.M., Paganelli F., et al. Fasting apo B48 level and coronary artery disease in a population without frank fasting hypertriglyceridemia. Metabolism 54 (2005) 1442-1447
32. Karpe F., Steiner G., Uffelman K., Olivecrona T., and Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 106 (1994) 83-97